COMMUNIQUÉS West-GlobeNewswire
-
QHSLab (OTCQB:USAQ) Reports Preliminary Unaudited 2025 Financial Results With Strong Revenue Growth, Expanding Margins, and Significant Debt Reduction
26/01/2026 -
Genyro Signs Exclusive License for “Sidewinder,” a Breakthrough DNA Construction Technology Featured in Nature
26/01/2026 -
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
26/01/2026 -
Primmune Therapeutics Announces Additional Close of Series B Financing
26/01/2026 -
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
26/01/2026 -
Leios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South Korea
26/01/2026 -
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
26/01/2026 -
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
26/01/2026 -
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
26/01/2026 -
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
26/01/2026 -
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
26/01/2026 -
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
26/01/2026 -
New Clinical Data Demonstrate that VIVUS’ QSYMIA® in Combination with Digitally Enhanced Lifestyle Interventions (DELI) Leads to Significantly Greater Reductions in Weight and Cardiovascular Risk Compared with DELI Alone in Adults with Obesity
26/01/2026 -
BlueOcean Global Announces FDA 510(k) Clearance of the Excelsior™ External Fixation System
26/01/2026 -
Nxera Pharma Webinar Presentation for FY2025 Financial Results
26/01/2026 -
HighLife Receives CE Mark Approval for its TMVR Solution
26/01/2026 -
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
26/01/2026 -
Lake Erie College of Osteopathic Medicine Designs Medical Education Around Multiple Learning Pathways to Support Different Learning Styles
26/01/2026 -
HighLife Receives CE Mark Approval for its TMVR Solution
26/01/2026
Pages